Opinion|Videos|March 24, 2025
Adoption of Emerging Delivery Systems and Future Outlook for NMIBC
Author(s)Karim Chamie, MD, MSHS
An expert discusses how TAR-200 shows promise for non–muscle invasive bladder cancer (NMIBC) treatment, with medical professionals optimistic about its targeted delivery, potentially improved outcomes, and transformative approach to bladder cancer management.
Advertisement
Video content above is prompted by the following:
- How easily can TAR-200 and other emerging delivery systems be adopted into clinical practice for the treatment of NMIBC?
- What are your thoughts on the future outlook for NMIBC?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves first-line Zenflow system for the treatment of BPH
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5
